{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:57:23Z","timestamp":1793829443149,"version":"4.6.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"8076","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2025,8,14]]},"DOI":"10.1038\/s41586-025-09203-8","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T11:03:20Z","timestamp":1751454200000},"page":"537-546","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["PPP2R1A mutations portend improved survival after cancer immunotherapy"],"prefix":"10.1038","volume":"644","author":[{"given":"Yibo","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Knisely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4436-838X","authenticated-orcid":false,"given":"Mitsutake","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7287-2877","authenticated-orcid":false,"given":"Minghao","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily M.","family":"Hinchcliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanghoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5888-3342","authenticated-orcid":false,"given":"Annalyn","family":"Welp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2130-3118","authenticated-orcid":false,"given":"Manoj","family":"Chelvanambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0780-3466","authenticated-orcid":false,"given":"Matthew","family":"Lastrapes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Jean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5799-6759","authenticated-orcid":false,"given":"Luis J.","family":"Montaner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-8756","authenticated-orcid":false,"given":"Jiakai","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ami","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrina","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Fellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renganayaki Krishna","family":"Pandurengan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin Roger Parra","family":"Cuentas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Celestino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3239-6658","authenticated-orcid":false,"given":"Jinsong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9832-9925","authenticated-orcid":false,"given":"R. Tyler","family":"Hillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-0156","authenticated-orcid":false,"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4242-1762","authenticated-orcid":false,"given":"Anil K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela T.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa A.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vining","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhakshinamoorthy","family":"Ganeshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3438-7576","authenticated-orcid":false,"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-6240","authenticated-orcid":false,"given":"Weiyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7255-2360","authenticated-orcid":false,"given":"Rugang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9380-0266","authenticated-orcid":false,"given":"Linghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4335-4151","authenticated-orcid":false,"given":"Amir A.","family":"Jazaeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"9203_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","volume":"5","author":"ML Disis","year":"2019","unstructured":"Disis, M. L. et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 5, 393 (2019).","journal-title":"JAMA Oncol."},{"key":"9203_CR2","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/JCO.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi, J. et al. Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in japan (NINJA). J. Clin. Oncol. 39, 3671\u20133681 (2021).","journal-title":"J. Clin. Oncol."},{"key":"9203_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","volume":"30","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann. Oncol. 30, 1080\u20131087 (2019).","journal-title":"Ann. Oncol."},{"key":"9203_CR4","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1200\/JCO.19.02059","volume":"38","author":"D Zamarin","year":"2020","unstructured":"Zamarin, D. et al. Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study. J. Clin. Oncol. 38, 1814\u20131823 (2020).","journal-title":"J. Clin. Oncol."},{"key":"9203_CR5","doi-asserted-by":"crossref","unstructured":"Liu Y. L. et al. BRCA mutations, homologous DNA repair deficiency, tumor mutational burden, and response to immune checkpoint inhibition in recurrent ovarian cancer. JCO Precis. Oncol. 4, 665\u2013679 (2020).","DOI":"10.1200\/PO.20.00069"},{"key":"9203_CR6","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","volume":"88","author":"T Sugiyama","year":"2000","unstructured":"Sugiyama, T. et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88, 2584\u20132589 (2000).","journal-title":"Cancer"},{"key":"9203_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ygyno.2017.08.004","volume":"147","author":"KE Oliver","year":"2017","unstructured":"Oliver, K. E. et al. An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: an NRG Oncology\/Gynecologic Oncology Group experience. Gynecol. Oncol. 147, 243\u2013249 (2017).","journal-title":"Gynecol. Oncol."},{"key":"9203_CR8","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/1471-0528.16264","volume":"127","author":"A Irodi","year":"2020","unstructured":"Irodi, A. et al. Patterns of clinicopathological features and outcome in epithelial ovarian cancer patients: 35 years of prospectively collected data. BJOG 127, 1409\u20131420 (2020).","journal-title":"BJOG"},{"key":"9203_CR9","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3389\/fonc.2019.00462","volume":"9","author":"M Remmerie","year":"2019","unstructured":"Remmerie, M. & Janssens, V. PP2A: a promising biomarker and therapeutic target in endometrial cancer. Front. Oncol. 9, 462 (2019).","journal-title":"Front. Oncol."},{"key":"9203_CR10","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/PAS.0000000000001432","volume":"44","author":"S Leskela","year":"2020","unstructured":"Leskela, S. et al. Mismatch repair deficiency in ovarian carcinoma: frequency, causes, and consequences. Am. J. Surg. Pathol. 44, 649\u2013656 (2020).","journal-title":"Am. J. Surg. Pathol."},{"key":"9203_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.18632\/oncotarget.755","volume":"4","author":"KH Yi","year":"2013","unstructured":"Yi, K. H., Axtmayer, J., Gustin, J. P., Rajpurohit, A. & Lauring, J. Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine. Oncotarget 4, 29\u201334 (2013).","journal-title":"Oncotarget"},{"key":"9203_CR12","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/cncr.34724","volume":"129","author":"KI Foster","year":"2023","unstructured":"Foster, K. I. et al. Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer. Cancer 129, 1672\u20131680 (2023).","journal-title":"Cancer"},{"key":"9203_CR13","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2020.31.e94","volume":"31","author":"E Kondo","year":"2020","unstructured":"Kondo, E. et al. The post-progression survival of patients with recurrent or persistent ovarian clear cell carcinoma: results from a randomized phase III study in JGOG3017\/GCIG. J. Gynecol. Oncol. 31, e94 (2020).","journal-title":"J. Gynecol. Oncol."},{"key":"9203_CR14","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","volume":"187","author":"MB Maxwell","year":"2024","unstructured":"Maxwell, M. B. et al. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell. 187, 3390\u20133408 (2024).","journal-title":"Cell."},{"key":"9203_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","volume":"24","author":"J Shen","year":"2018","unstructured":"Shen, J. et al. ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat. Med. 24, 556\u2013562 (2018).","journal-title":"Nat. Med."},{"key":"9203_CR16","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abc4220","volume":"12","author":"S Goswami","year":"2020","unstructured":"Goswami, S. et al. ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC. Sci. Transl. Med. 12, eabc4220 (2020).","journal-title":"Sci. Transl. Med."},{"key":"9203_CR17","doi-asserted-by":"publisher","first-page":"776","DOI":"10.7150\/jca.41296","volume":"11","author":"T Jiang","year":"2020","unstructured":"Jiang, T., Chen, X., Su, C., Ren, S. & Zhou, C. Pan-cancer analysis of ARID1A alterations as biomarkers for immunotherapy outcomes. J. Cancer 11, 776\u2013780 (2020).","journal-title":"J. Cancer"},{"key":"9203_CR18","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7, 306 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"9203_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527\u2013541 (2022).","journal-title":"Immunity"},{"key":"9203_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"9203_CR21","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","volume":"577","author":"R Cabrita","year":"2020","unstructured":"Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561\u2013565 (2020).","journal-title":"Nature"},{"key":"9203_CR22","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1038\/s41587-022-01483-z","volume":"40","author":"S He","year":"2022","unstructured":"He, S. et al. High-plex imaging of RNA and proteins at subcellular resolution in fixed tissue by spatial molecular imaging. Nat. Biotechnol. 40, 1794\u20131806 (2022).","journal-title":"Nat. Biotechnol."},{"key":"9203_CR23","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adg7995","volume":"9","author":"D Barras","year":"2024","unstructured":"Barras, D. et al. Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8+ T-myeloid cell networks in melanoma. Sci. Immunol. 9, eadg7995 (2024).","journal-title":"Sci. Immunol."},{"key":"9203_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41580-024-00768-2","volume":"26","author":"GS Gulati","year":"2025","unstructured":"Gulati, G. S., D\u2019Silva, J. P., Liu, Y., Wang, L. & Newman, A. M. Profiling cell identity and tissue architecture with single-cell and spatial transcriptomics. Nat. Rev. Mol. Cell Biol. 26, 11\u201331 (2025).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"9203_CR25","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153\u2013167 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"9203_CR26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"9203_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"},{"key":"9203_CR28","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","volume":"4","author":"A Ribas","year":"2016","unstructured":"Ribas, A. et al. PD-1 blockade expands intratumoral memory T cells. Cancer Immunol. Res. 4, 194\u2013203 (2016).","journal-title":"Cancer Immunol. Res."},{"key":"9203_CR29","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell 35, 238\u2013255 (2019).","journal-title":"Cancer Cell"},{"key":"9203_CR30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ejca.2016.12.031","volume":"75","author":"JK Tietze","year":"2017","unstructured":"Tietze, J. K. et al. The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab. Eur. J. Cancer 75, 268\u2013279 (2017).","journal-title":"Eur. J. Cancer"},{"key":"9203_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/s41586-020-2746-2","volume":"586","author":"KA Lawson","year":"2020","unstructured":"Lawson, K. A. et al. Functional genomic landscape of cancer-intrinsic evasion of killing by T cells. Nature 586, 120\u2013126 (2020).","journal-title":"Nature"},{"key":"9203_CR32","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770\u2013775 (2018).","journal-title":"Science"},{"key":"9203_CR33","doi-asserted-by":"publisher","first-page":"e001819","DOI":"10.1136\/jitc-2020-001819","volume":"9","author":"J Hou","year":"2021","unstructured":"Hou, J. et al. Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J. Immunother. Cancer 9, e001819 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"9203_CR34","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ncb3582","volume":"19","author":"BG Bitler","year":"2017","unstructured":"Bitler, B. G. et al. ARID1A-mutated ovarian cancers depend on HDAC6 activity. Nat. Cell Biol. 19, 962\u2013973 (2017).","journal-title":"Nat. Cell Biol."},{"key":"9203_CR35","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1158\/0008-5472.CAN-19-1302","volume":"79","author":"T Fukumoto","year":"2019","unstructured":"Fukumoto, T. et al. HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. Cancer Res. 79, 5482\u20135489 (2019).","journal-title":"Cancer Res."},{"key":"9203_CR36","doi-asserted-by":"crossref","unstructured":"Gao J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","DOI":"10.1126\/scisignal.2004088"},{"key":"9203_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"9203_CR38","doi-asserted-by":"publisher","first-page":"3962","DOI":"10.1158\/1078-0432.CCR-18-3691","volume":"25","author":"M Takenaka","year":"2019","unstructured":"Takenaka, M. et al. Survival following chemotherapy in ovarian clear cell carcinoma is not associated with pathological misclassification of tumor histotype. Clin. Cancer Res. 25, 3962\u20133973 (2019).","journal-title":"Clin. Cancer Res."},{"key":"9203_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04425-z","volume":"9","author":"WS Ho","year":"2018","unstructured":"Ho, W. S. et al. Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade. Nat. Commun. 9, 2126 (2018).","journal-title":"Nat. Commun."},{"key":"9203_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/nature12988","volume":"506","author":"P Zhou","year":"2014","unstructured":"Zhou, P. et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 506, 52\u201357 (2014).","journal-title":"Nature"},{"key":"9203_CR41","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/ni.3390","volume":"17","author":"SA Apostolidis","year":"2016","unstructured":"Apostolidis, S. A. et al. Phosphatase PP2A is requisite for the function of regulatory T cells. Nat. Immunol. 17, 556\u2013564 (2016).","journal-title":"Nat. Immunol."},{"key":"9203_CR42","first-page":"2333","volume":"18","author":"MC Clark","year":"2024","unstructured":"Clark, M. C. et al. A combination of protein phosphatase 2A inhibition and checkpoint immunotherapy: a perfect storm. Mol. Oncol. 18, 2333\u20132337 (2024).","journal-title":"Mol. Oncol."},{"key":"9203_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27620-x","volume":"12","author":"YT Yen","year":"2021","unstructured":"Yen, Y. T. et al. Protein phosphatase 2A inactivation induces microsatellite instability, neoantigen production and immune response. Nat. Commun. 12, 7297 (2021).","journal-title":"Nat. Commun."},{"key":"9203_CR44","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1158\/0008-5472.CAN-22-3382","volume":"83","author":"I Mondal","year":"2023","unstructured":"Mondal, I. et al. PP2Ac deficiency enhances tumor immunogenicity by activating STING-type i interferon signaling in glioblastoma. Cancer Res. 83, 2527\u20132542 (2023).","journal-title":"Cancer Res."},{"key":"9203_CR45","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.1172\/JCI99317","volume":"128","author":"J Hsu","year":"2018","unstructured":"Hsu, J. et al. Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade. J. Clin. Invest. 128, 4654\u20134668 (2018).","journal-title":"J. Clin. Invest."},{"key":"9203_CR46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI164809","volume":"133","author":"J Huuhtanen","year":"2023","unstructured":"Huuhtanen, J. et al. Single-cell characterization of anti-LAG-3 and anti-PD-1 combination treatment in patients with melanoma. J. Clin. Invest. 133, e164809 (2023).","journal-title":"J. Clin. Invest."},{"key":"9203_CR47","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1158\/2159-8290.CD-22-0686","volume":"13","author":"RD Chow","year":"2023","unstructured":"Chow, R. D. et al. Distinct mechanisms of mismatch-repair deficiency delineate two modes of response to anti-PD-1 immunotherapy in endometrial carcinoma. Cancer Discov. 13, 312\u2013331 (2023).","journal-title":"Cancer Discov."},{"key":"9203_CR48","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1002\/cncr.35126","volume":"130","author":"EM Hinchcliff","year":"2024","unstructured":"Hinchcliff, E. M. et al. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer 130, 1061\u20131071 (2024).","journal-title":"Cancer"},{"key":"9203_CR49","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1373\/clinchem.2014.231100","volume":"61","author":"K Chen","year":"2015","unstructured":"Chen, K. et al. Clinical actionability enhanced through deep targeted sequencing of solid tumors. Clin. Chem. 61, 544\u2013553 (2015).","journal-title":"Clin. Chem."},{"key":"9203_CR50","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412\u20137420 (2009).","journal-title":"Clin. Cancer Res."},{"key":"9203_CR51","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/bioinformatics\/bts196","volume":"28","author":"DS DeLuca","year":"2012","unstructured":"DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530\u20131532 (2012).","journal-title":"Bioinformatics"},{"key":"9203_CR52","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"9203_CR53","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"9203_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"9203_CR55","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545\u201315550 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"9203_CR56","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284\u2013287 (2012).","journal-title":"OMICS"},{"key":"9203_CR57","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst. 1, 417\u2013425 (2015).","journal-title":"Cell Syst."},{"key":"9203_CR58","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","volume":"125","author":"Y Benjamini","year":"2001","unstructured":"Benjamini, Y., Drai, D., Elmer, G., Kafkafi, N. & Golani, I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res. 125, 279\u2013284 (2001).","journal-title":"Behav Brain Res."},{"key":"9203_CR59","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman, A. M. et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat. Biotechnol. 37, 773\u2013782 (2019).","journal-title":"Nat. Biotechnol."},{"key":"9203_CR60","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41592-021-01142-2","volume":"18","author":"L Song","year":"2021","unstructured":"Song, L. et al. TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data. Nat. Methods 18, 627\u2013630 (2021).","journal-title":"Nat. Methods"},{"key":"9203_CR61","doi-asserted-by":"crossref","unstructured":"Rodriguez, S., Sun, B., McAllen, S., Jiang, M. & Parra, E. R. Multiplexed barcoding image analysis for immunoprofiling and spatial mapping characterization in the single-cell analysis of paraffin tissue samples. J. Vis. Exp. 194, e64758 (2023).","DOI":"10.3791\/64758"},{"key":"9203_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 16878 (2017).","journal-title":"Sci. Rep."},{"key":"9203_CR63","doi-asserted-by":"publisher","unstructured":"Schmidt U., Weigert M., Broaddus C., Myers G. Cell detection with star-convex polygons. In Proc. Medical Image Computing and Computer Assisted Intervention\u2014MICCAI 2018 (eds Frangi, A. F. et al.) Vol. 11071, 265\u2013273 (Springer, 2018); https:\/\/doi.org\/10.1007\/978-3-030-00934-2_30.","DOI":"10.1007\/978-3-030-00934-2_30"},{"key":"9203_CR64","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","volume":"38","author":"MF Richter","year":"2020","unstructured":"Richter, M. F. et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat. Biotechnol. 38, 883\u2013891 (2020).","journal-title":"Nat. Biotechnol."},{"key":"9203_CR65","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1038\/s41556-020-0518-8","volume":"22","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Increasing the efficiency and targeting range of cytidine base editors through fusion of a single-stranded DNA-binding protein domain. Nat. Cell Biol. 22, 740\u2013750 (2020).","journal-title":"Nat. Cell Biol."},{"key":"9203_CR66","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47069-y","volume":"15","author":"H Nie","year":"2024","unstructured":"Nie, H. et al. Targeting branched N-glycans and fucosylation sensitizes ovarian tumors to immune checkpoint blockade. Nat. Commun. 15, 2853 (2024).","journal-title":"Nat. Commun."},{"key":"9203_CR67","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","volume":"34","author":"IC Nicholson","year":"1997","unstructured":"Nicholson, I. C. et al. Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma. Mol. Immunol. 34, 1157\u20131165 (1997).","journal-title":"Mol. Immunol."},{"key":"9203_CR68","doi-asserted-by":"publisher","first-page":"e1006613","DOI":"10.1371\/journal.ppat.1006613","volume":"13","author":"RS Leibman","year":"2017","unstructured":"Leibman, R. S. et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog. 13, e1006613 (2017).","journal-title":"PLoS Pathog."},{"key":"9203_CR69","doi-asserted-by":"publisher","first-page":"7728","DOI":"10.1128\/JVI.00860-16","volume":"90","author":"Z Yuan","year":"2016","unstructured":"Yuan, Z. et al. Recapitulating cross-species transmission of simian immunodeficiency virus SIVcpz to humans by using humanized BLT mice. J. Virol. 90, 7728\u20137739 (2016).","journal-title":"J. Virol."},{"key":"9203_CR70","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ccell.2023.03.002","volume":"41","author":"W Zhou","year":"2023","unstructured":"Zhou, W. et al. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell 41, 740\u2013756 (2023).","journal-title":"Cancer Cell"}],"updated-by":[{"DOI":"10.1038\/s41586-025-09586-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000}}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09203-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09203-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09203-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T15:43:16Z","timestamp":1757259796000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-025-09203-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":70,"journal-issue":{"issue":"8076","published-print":{"date-parts":[[2025,8,14]]}},"alternative-id":["9203"],"URL":"https:\/\/doi.org\/10.1038\/s41586-025-09203-8","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41586-025-09586-8","asserted-by":"object"}]},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"13 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41586-025-09586-8","URL":"https:\/\/doi.org\/10.1038\/s41586-025-09586-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.K.S. reports a consulting role at Merck, Onxeo, ImmunoGen, GSK, Astra Zeneca and Iylon. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}